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Fluorescence-guided surgical sampling of glioblastoma identifies
phenotypically distinct tumour-initiating cell populations in the
tumour mass and margin
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BACKGROUND: Acquiring clinically annotated, spatially stratified tissue samples from human glioblastoma (GBM) is compromised by
haemorrhage, brain shift and subjective identification of ‘normal’ brain. We tested the use of 5-aminolevulinic acid (5-ALA)
fluorescence to objective tissue sampling and to derive tumour-initiating cells (TICs) from mass and margin.
METHODS: The 5-ALA was administered to 30 GBM patients. Samples were taken from the non-fluorescent necrotic core, fluorescent
tumour mass and non-fluorescent margin. We compared the efficiency of isolating TICs from these areas in 5-ALA versus control
patients. HRMAS 1H NMR was used to reveal metabolic alterations due to 5-ALA. We then characterised TICs for self-renewal
in vitro and tumorigenicity in vivo.
RESULTS: The derivation of TICs was not compromised by 5-ALA and the metabolic profile was similar between tumours from 5-ALA
patients and controls. The TICs from the fluorescent mass were self-renewing in vitro and tumour-forming in vivo, whereas TICs from
non-fluorescent margin did not self-renew in vitro but did form tumours in vivo.
CONCLUSION: Our data show that 5-ALA does not compromise the derivation of TICs. It also reveals that the margin contains TICs,
which are phenotypically different from those isolated from the corresponding mass.
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Human glioblastoma (GBM) is the most aggressive adult primary
brain tumour. Conventional therapies provide minimal benefits and
median survival is approximately 14 months (Stupp et al, 2005).
The GBM recurs within 2 cm of the resected tumour, despite
chemotherapy and radiotherapy. This tumour invades the adjacent
brain and it is impossible to surgically determine the extent of this
infiltration. Thus, the tumour border, as determined surgically,
is very subjective and is currently mainly based on the visual
appearance of the tissue correlated with intra-operative neuro-
navigation and imaging. The recent development of fluorescence-
guided surgical resection of high-grade glioma, including GBM,
aims at assisting the surgeons in identifying tumour cells and has
been demonstrated to increase tumour removal and improve
progression-free survival (Stummer et al, 2000). Fluorescence-
guided resection is based on the use of 5-aminolevulinic acid
(5-ALA), an endogenous intermediate of the porphyrin biosynth-
esis pathway. It acts as a prodrug that is metabolised intracellularly,
leading to the selective accumulation of the fluorescent molecule
protoporphyrin IX (PpIX) in tumour cells (Stummer et al, 1998).
Peri-operative fluorescence allows objective discrimination of
necrotic material (N), which is non-fluorescent, tumour mass
(T) which is fluorescent, and tumour margin (M), which is
non-fluorescent (Roberts et al, 2011; Idoate et al, 2011). N and M
tissues can be easily discriminated based on macroscopic evidence
of necrotic material and the margin appearing macroscopically as
normal tissue at the tumour border. The absence of fluorescence is
a potential objective surgical end point for standardising the
resection, and also facilitating interrogation of distinct tumour
areas. In this context, it has also been recently reported that PpIX
concentration is higher in areas of increasing malignancy in
gliomas (Valdes et al, 2011) and that fluorescence-guided resection
can be used to assist the evaluation of expression of Nestin and
Ki67 at the tumour border and to study the tumour–brain tissue
interface (Idoate et al, 2011).
In the last decade, it has been demonstrated that human brain
tumours, in particular GBM, contain tumour-initiating cells (TICs)
(Ignatova et al, 2002; Hemmati et al, 2003; Singh et al, 2003; Galli
et al, 2004; Singh et al, 2004; Yuan et al, 2004) and it has been
proposed that it is necessary to eradicate these cells in order to
block tumour regrowth (Reya et al, 2001). More recently, it has
been demonstrated that distinct TICs that have genetically
diverged from a common ancestor co-exist in the same GBM
(Piccirillo et al, 2009b) and may provide the basis for recurrence.
As 5-ALA helps to identify the high-grade malignant disease
during surgery, we wanted to test if the use of 5-ALA could
compromise derivation of TICs and could be used to identify
TICs in M.
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MATERIALS AND METHODS
Patient recruitment and sample collection
The project received approval from the UK National Research
Ethics Service and the University of Cambridge National Health
Service Foundation Trust Research and Development department.
All patients and imaging data sets were reviewed pre-operatively at
the specialist Neuro-oncology multi-disciplinary team and subse-
quently seen in our dedicated research clinic (Guilfoyle et al,
2011). A total of 40 patients with a radiological diagnosis of GBM
were recruited and written informed consent was obtained pre-
operatively. There were 23 men and 17 women. Mean age was 59.9
years at diagnosis (range 32–77) (see Supplementary Table 1).
To assess the impact of 5-ALA on TIC derivation, 10 patients were
administered with 5-ALA (5-ALAþ ve GBMs) (Medac, Stirling, UK)
and 10 patients did not (5-ALA ve GBMs). The 5-ALA was
administered orally (20mgkg 1) (Tonn and Stummer, 2008) 5 h
before surgery. Samples were taken from T using image guidance to
identify where the sample was taken. Each sample taken was divided
in two parts: one part for cell derivation and other for
histopathological analysis. Further, 20 patients were recruited for
sampling and N, T and M specimens were obtained from each.
Cytoreductive surgery and tissue sampling was performed using
a Zeiss OPMI Pentero operating microscope (Zeiss, Welwyn
Garden City, UK) with a xenon lamp providing a 405-nm light
source for excitation (Zeiss) and a 620–710-nm bandpass filter for
detection of PpIX fluorescence (Zeiss). ‘Fluorescence’ was defined
as ‘visible fluorescence using the operating microscope’ as
described above. The tissues collected corresponded to no, low,
moderate and highly fluorescent material (levels 0, 1, 2 and 3) as
previously reported (Valdes et al, 2011). Because of the subjective
nature of the ‘low’ and ‘moderate’ distinction during surgery, we
adopted a binary approach: tissue was either visibly pink or it was
not. Tissue was subsequently analysed accordingly. N and M were
not visibly pink and T was visibly pink. This is a pragmatic
approach that can be easily applied in the operating room.
Cell-derivation and tumour-formation assay
Primary culture, culture derivation and propagation were performed
as previously described (Piccirillo et al, 2009b; Fael Al-Mayhani
et al, 2009). Immunofluorescence assays were performed for the
following markers: glial fibrillary acidic protein (GFAP), class III
b-tubulin (Tuj1) and oligodendrocyte marker (O4) were performed
as described by (Piccirillo et al, 2009b).
All animal procedures were performed according to the Home
Office UK guidelines. Intracerebral transplantation of 3 105 GBM
cells into the right striatum of 4-week-old Nod/Scid mice was
performed as previously described (Piccirillo et al, 2009b). The GBM
cells used for transplantation were either uncultured (‘directly
from patients’) or propagated in vitro for two passages (‘briefly
cultured’) in serum-free (SF) media before injection (Piccirillo
et al, 2009b; Fael Al-Mayhani et al, 2009). Animals were killed
when symptomatic.
Real-time expression analysis of TICs from human GBM
Total RNA was extracted from T and M cells from briefly cultured
cells of three samples from 5-ALAþ ve GBMs. TRIzol (Invitrogen,
Paisley, UK) was used according to the manufacturer’s instructions.
Before the synthesis of the first-strand complementary DNA
(cDNA), RNA was treated with DNase (Qiagen, Crawley, UK). The
cDNA was synthesised from 5mg of total RNA using Random
Primers (Invitrogen) and a Superscript III First-Strand Synthesis
System for real-time PCR (RT–PCR) (Invitrogen). The RT–PCR for
Ki67, Nestin, GFAP, Sox2 and Notch2 transcripts was performed
using CFX96 RT–PCR (Biorad, Hemel Hempstead, UK), RT2 qPCR
Primer Assay and RT2 SYBR Green qPCR Master Mix (SABio-
sciences, Qiagen, Crawley, UK) according to the manufacturer’s
instructions. The 18S was used as the housekeeping reference.
Relative expression quantification was performed by the DDCT
method (Livak and Schmittgen, 2001). All the experiments were
performed in triplicate and each triplicate was repeated three times.
Histopathology
Haematoxylin and Eosin (H&E) staining was performed on 4 mm
formalin-fixed, paraffin-embedded GBM tissue, either derived
from patients or from orthotopic transplantation of 3 105 GBM
cells as described above. For human tissues, a single neuropatho-
logist analysed the H&E tissue slides when blinded to the clinical,
radiographical and pathological diagnoses derived from the main
surgical specimen in each case.
Immunohistochemistry for GFAP was carried out according to
the manufacturer’s instruction (Dako, Stockport, UK).
HRMAS 1H NMR ANALYSIS OF TISSUE METABOLISM
Experimental procedure
For metabolite analysis by using HRMAS 1H NMR, tissues from 10
5-ALAþ ve GBMs and 10 5-ALA ve GBMs were collected in
B50mg pieces into 2ml tubes, instantaneously transferred to dry
ice (frozen CO2) and transported to the laboratory where each tube
was transferred to liquid nitrogen for storage. The protocol
published previously was followed (Opstad et al, 2008) with the
following changes. On the day of assay, the tissue was cut into
B10mg pieces on dry ice without thawing in a microbiological
safety level 2 cabinet. A total of 10 ml sodium formate
(100mgml 1) was added as an internal standard for calibration
of chemical shift to a disposable rotor insert. The tissue was
inserted into the insert and the insert opening was closed with a
screw cap. The total weight of the insert with the sample was noted.
Then the insert was transferred to a 50ml HRMAS rotor (made of
ZrO2) (Bruker Biospin, Coventry, UK) and stored at 4 1C until the
start of the measurement. The experiment was performed in a
Bruker AVANCE NMR spectrometer (Bruker Biospin) operating at
600MHz for protons. HRMAS 1H NMR analysis was performed
using a 5-kHz spinning frequency and at 4 1C temperature. The
HRMAS 1H NMR data acquisition included shimming and pulse-
angle calibration for each sample. Water-suppressed 1H spectra
were acquired for metabolite analysis with a repetition time of 8 s
(total acquisition time 15min). A water-suppressed CPMG
sequence (T2 filter times of 50, 100 and 200ms) was used to give
lipid and macromolecule-free HRMAS 1H NMR spectra. Unsup-
pressed water signal was used for metabolite quantitation.
Pattern analysis using principal component analysis (PCA)
The region between 0.5 and 4.5p.p.m. of the HRMAS 1H NMR
spectrum was analysed using 0.01p.p.m.-sized integration steps (so-
called buckets). Two regions were excluded from the analysis
(1.15–1.21 and 3.7–3.65p.p.m.), as the signals found in these regions
correspond to ethyl alcohol. The mean centred values of the buckets
were analysed by unsupervised PCA and visualised in two-dimensional
PCA maps. The score plot pictures the relationship of samples to one
another according to the chosen principal components.
Linear combination model
Metabolite quantitation from HRMAS 1H NMR spectra was
performed by using LCModel (Provencher, 2001) with a basis set
that had been used in an earlier study (Opstad et al, 2008). The
unsuppressed tissue water signal from the 1H NMR spectra was
used to estimate absolute concentrations. The set of metabolites
analysed included alanine, acetate, aspartate, choline, creatine,
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gamma aminobutyric acid, glucose, glutamine, glutamate, glycine,
glycerophosphocholine, glutathione, inositol, lactate, leucine,
lysine, N-acetyl aspartate, N-acetyl aspartylglutamate, phospho-
choline, phosphorylethanolamine, scyllo-inositol and taurine.
Additionally a number of lipid (Lip) and macromolecular (MM)
peaks were analysed, wherein the number after Lip/MM corre-
sponds to the chemical shift of the HRMAS 1H NMR peak
(e.g., Lip13a is identified by a lipid peak at 1.3 p.p.m.). The
following lipids and macromolecules were analysed: Lip13a,
MM14, Lip09b, MM09, Lip15, MM17, Lip205, MM205, MM225,
MM32a, MM32b, MM30, Lip28b, Lip28a, MM12 and MM18.
Statistical analysis
Statistical analysis was performed using Microsoft Excel and SPSS
(IBM, Portsmouth, UK). Normality was tested using the
Kolmogorov–Smirnov test. Pairwise comparisons between T and
M from the same GBMs were made using paired t-tests. An alpha
of o0.05 (P-value o0.05) was considered significant. All error
bars represent s.e.m.
RESULTS
The 5-ALA does not affect the isolation and propagation of
TICs from human GBM
Using techniques for in vitro derivation and propagation of TICs
previously reported (Galli et al, 2004; Piccirillo et al, 2009b; Fael Al-
Mayhani et al, 2009), we compared the efficiency of isolation of TICs
from T in 10 5-ALAþ ve versus 5-ALA ve GBMs. We first
identified fluorescent tissue (Figure 1A) and we confirmed that it
was tumour (Table 1 and Supplementary Figure 1) according to
previous findings demonstrating that 5-ALA identifies solid tumour
with 100% positive predictive value and that high concentration of
PpIX strongly correlates with tissue malignancy (Valdes et al, 2011;
Idoate et al, 2011). We have previously isolated TICs from 20 GBM
samples prior to the use of 5-ALA according to the Cambridge
protocol previously described (Fael Al-Mayhani et al, 2009) and we
adopted the same protocol to derive new TICs from 5-ALAþ ve
GBMs. We verified that 5-ALA does not affect the isolation
(Figure 1B), propagation, clonogenic index (Figure 1C) and multi-
potency (Figure 1D) of TICs. Isolation of TICs in SF media (Fael Al-
Mayhani et al, 2009) from 10 5-ALAþ ve GBMs occurred with 100%
efficiency. We observed sphere-forming capacity and clonogenicity
in all the 10 analysed samples in SF media, as previously reported
(Piccirillo et al, 2009b; Fael Al-Mayhani et al, 2009).
Metabolic profiles of GBM samples from 5-ALAþ ve and
5-ALA ve patients reveal strong similarity
As 5-ALA is an intermediate of the porphyrin biosynthesis pathway
and is converted by the tumour cells into PpIX, we asked whether its
use could alter the metabolism of tumour cells or lead to selection of
tumour cells with active biosynthesis. Although studies on metabolic
alteration induced by 5-ALA in tumours have not been described in the
literature, it has been observed that metabolic diseases characterised by
accumulation of 5-ALA can cause alteration of tryptophan metabolism
(Lelli et al, 2008) and could be partly related to glucose metabolism
disturbances (Lelli et al, 2005).
Therefore, we compared the metabolic profiles of TICs of 10
5-ALAþ ve versus 10 5-ALA ve GBMs by using HRMAS 1H NMR
spectroscopy. We performed the analysis using B10mg of tissue
from the samples that were subsequently used for cell culture. We
found no significant difference in the metabolite levels estimated
in the 1H NMR spectra (Figure 1E and Supplementary Table 2)
or by PCA of the 1H NMR data (data not shown) when the
data from 5-ALAþ ve GBMs was compared with those from
5-ALA ve GBMs.
The TICs isolated from 5-ALAþ ve GBMs are tumorigenic
The cardinal feature of TICs from GBM is that they develop
tumours upon orthotopic injection into the brains of immuno-
suppressed animals (Vescovi et al, 2006). A bona fide TIC
population is tumorigenic in vivo when cells are injected directly
from a patient’s sample or after a brief expansion in vitro in SF
media (Piccirillo et al, 2006).
We verified the in vivo tumorigenicity of TICs isolated from four
5-ALAþ ve versus four 5-ALA ve GBMs by performing ortho-
topic injection into the brains of Nod/Scid mice. We found that
TICs both ‘directly from patients’ and ‘briefly cultured’ retained
tumorigenic potential, as demonstrated by tumour formation with
an engraftment rate of 100% (Figures 1F, left and 2E). Histological
analysis of these xenografts confirmed the presence of a T
(Figure 1F, left) of glial nature, as demonstrated by GFAP
immunoreactivity (Figure 1F, right). These data demonstrate that
5-ALA does not impair the tumorigenicity of TICs.
Histopathological analysis and in vitro characterisation of
non-fluorescent regions in 5-ALAþ ve GBMs reveal
different cell phenotypes
The use of 5-ALA also provides us with a unique opportunity for
objectively identifying and characterising malignant tissue. As
previously reported (Roberts et al, 2011; Idoate et al, 2011), the N
and M tissues in 5-ALAþ ve GBMs do not fluorescence under the
described peri-operative conditions for fluorescence imaging. We
therefore compared N and M regions of the tumour in 20
5-ALAþ ve GBMs.
We first established the absence of visible fluorescent material in
M and N tissues using the OPMI Pentero operating microscope
(Zeiss), and we confirmed by histological analysis the presence of
necrotic material in N and a few scattered tumour cells in M
(Table 1 and Supplementary Figure 1). Following the enzymatic
dissociation of corresponding tissue, we found that in SF media, N
consistently gave rise to primary cultures containing dead cells
(Figure 2A, left), as expected from necrotic material. Conversely,
viable cells could be found in M, which did not demonstrate self-
renewal (Figure 2A, right) and long-term proliferation in SF media
with the current protocol (Figure 2B) (Piccirillo et al, 2009b; Fael
Al-Mayhani et al, 2009). Sphere formation and clonogenicity was
observed only in 10% of the cases for M tissue (data not shown).
We evaluated the expression of the proliferation marker Ki67 on M
versus T cells for three different samples by RT–PCR and we
confirmed that the proliferative index of M cells was statistically
significantly lower in comparison with T cells (P o0.01, M versus
T cells, Figure 2C).
Margin cells do not possess a ‘stem-cell molecular
signature’ but retain tumour-initiating ability
As it has been suggested that the margin of GBM represents an
invasive niche where TIC maintenance is supported (Lathia et al,
2011), we performed a molecular characterisation of M versus
T cells to verify if M cells express markers of TICs.
We performed gene-expression analysis for stem-cell markers
by RT–PCR. We selected the following markers: Nestin, GFAP,
Sox2 and Notch2, which have been previously shown to identify
neural stem cells and to regulate their self-renewal and prolifera-
tion (Gaiano and Fishell, 2002; Sanai et al, 2004; Ferri et al, 2004;
Shen et al, 2004; Vescovi et al, 2006) and have been retrieved in
TICs from GBM (Hemmati et al, 2003; Piccirillo et al, 2006;
Gangemi et al, 2009; Fan et al, 2010).
By comparing M-cell gene expression with that of corresponding
T cells from the same tumour, we found that M cells did not
exhibit the same molecular signature typical of cells isolated from
corresponding T (Po0.05, M versus T cells, Figure 2D). Because of
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Figure 1 The TICs can be isolated using GBM samples obtained from 5-ALA-administered patients. (A) Human brain under the light (left) and the
fluorescence microscope (right) during resection of GBM. The 5-ALA technology allows us to discriminate between three areas of disease in human GBM:
fluorescent tumour mass (T), non-fluorescent necrotic area (N) and non-fluorescent margin (M). (B) In vitro, cells isolated from T of 5-ALAþ ve GBMs (left)
and cultured in SF media grow as neurospheres (right) as previously reported (Piccirillo et al, 2009b; Fael Al-Mayhani et al, 2009) (Magnification  100;
scale bar, 50mm). (C) Cells isolated from T of 5-ALAþ ve GBMs are long-term expanding (left) and clonogenic as the cells isolated from T in 5-ALA ve
samples (right). Note that SP6 and SP18 TICs are derived from 5-ALA ve GBMs and SP10 and SP20 TICs are established from 5-ALAþ ve GBMs.
(D) Upon in vitro differentiation, T cells from 5-ALAþ ve GBMs resemble the phenotypes of normal neural stem cells by expressing astroglial and neuronal
markers (GFAP, green and Tuj1, fuchsia; left) and oligodendroglial-markers (O4, red; right) (Magnification  400; scale bar, 20mm). (E) Representative
HRMAS spectra of 5-ALAþ ve GBM (top) and 5-ALA ve GBM (bottom). Clearly visible peaks are annotated in both spectra. One example is shown as
representative of 10 5-ALAþ ve GBMs and 10 5-ALA ve GBMs giving similar results. (F) Xenograft obtained upon injection of T cells of a 5-ALAþ ve
GBM. The H&E staining reveals the presence of tumour (left) and GFAP immunoreactivity (green; right) confirms the glial nature of the tumour,
counterstained with 4’,6-diamidino-2-phenylindole dihydrochloride (Magnification  200; scale bar, 100mm). Abbreviations: TM¼ tumour mass and C¼ core.
Table 1 Histological analysis confirms that fluorescence-guided resection identifies tumour mass, necrotic material and tumour margin
Tissue T N M
Fluorescence ‘þ ’ ‘ ’ ‘ ’
Histological features Solid tumour with Presence of inflammatory cells Not solid tumour with
microvascular proliferation in 95% necrotic material very few tumour cells
and small areas of necrosis and 5% tumour cells (approximately 10% of
(10% of the total surface area) (% of total surface area) total cells)
Histological analysis of T, M and N samples obtained from the same tumour confirmed that the cardinal features of glioblastoma were present in T. Conversely, N comprised
mainly necrotic material and M was composed of normal cells with a few tumour cells.
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Figure 2 Margin area in GBM contains a distinct population of TICs. (A) In vitro, primary cells isolated from N (left) and M (right) of 5-ALAþ ve GBMs do not
grow in SF media (Magnification  100; scale bar, 20mm). (B) Growth-curve analysis show that only cells derived from the T are capable of long-term expansion.
On the contrary, N cells die in a few passages. M cells are not capable of long-term proliferation in these culture conditions. This analysis has been repeated on
20 sets of samples (T, M and N) giving similar results. (C) RT– PCR shows that the proliferation marker Ki67 is significantly less expressed in M cells in comparison
with T cells (n¼ 3) in accordance to the growth-curve analysis shown in B. The number of data points included in each sample is 3. (D) M cells show a poor ‘stem-
cell molecular signature’ in comparison with their corresponding T cells. Gene expression of Ki67, Nestin, Gfap, Sox2 and Notch2 has been evaluated using 18S as
housekeeping (n¼ 3). The number of data points included in each sample is 3. (E) Table summarising the tumorigenic ability of M versus T cells in four samples.
Cells were injected uncultured (directly from patients) or briefly cultured in vitro for two passages in SF media before injection into the brain of Nod/Scid mice.
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the differences in cell phenotype and molecular signature
compared with TICs isolated from T samples, we hypothesised
that M cells would not be tumorigenic in vivo.
Quite unexpectedly, orthotopic inoculation of M cells of four
patients as cells obtained ‘directly from patients’ or ‘briefly
cultured in vitro’ showed that M cells retain tumorigenicity
in vivo (Figure 2E). Only the M cells from sample SP19 revealed a
very low tumorigenic potential with only one animal out of three
developing a tumour mass, giving an engraftment rate of 33%. This
could be due to the fact that in this experiment M cells were
injected as a ‘directly from patient’ sample and may have
contained very few or no malignant cells (Supplementary
Figure 1). Further research will be needed to better characterise
this area of the disease.
DISCUSSION
The use of 5-ALA has been extensively investigated as a means of
performing a better surgical resection in patients diagnosed with
GBM (Stummer et al, 2006). Recently, it has been reported that
fluorescence-guided resection can permit the separation of
malignant tissue from areas of putative healthy tissue at the
histological level (Idoate et al, 2011). Fluorescence emission is also
reported to correlate with histopathological markers that identify
regions of increased malignancy in glioma (Valdes et al, 2011) and
WHO grade (Roberts et al, 2011).
Our data reveal that 5-ALA does not compromise derivation of
TICs and does not select for a subpopulation of metabolically
distinct cells. The detection of visible fluorescence in T and
absence of visible fluorescence in N and M regions allows
pragmatic, real-time objective sampling of distinct tumour areas
in GBM during surgery (our strategy is summarised in the cartoon
presented as Supplementary Figure 2).
We started our analysis by showing that the fluorescent T contains
TICs that can be efficiently derived by culture in SF media with
high efficiency (Piccirillo et al, 2009b; Fael Al-Mayhani et al, 2009).
We go on to show for the first time that the non-fluorescent M
contains a distinct cell population that is tumorigenic in vivo but is
not self-renewing in vitro under the conditions used. This is in line
with previous findings, suggesting that different TICs can co-exist
in the same patient tumour (Piccirillo et al, 2009b) and that self-
renewal is not an essential pre-requisite for tumour formation in
mouse models of high-grade gliomas (Barrett et al, 2012).
Our strategy is based on functional assays developed for the
identification of TICs (Vescovi et al, 2006; Fael Al-Mayhani et al
2009). It is marker-independent, because no universal marker for
human GBM is available to date (Piccirillo et al, 2009a). Our
in vivo data are limited to the mouse-recipient strain, which we
have been using for this study (Nod/Scid mice), and we are aware
that the use of different mouse recipients can have an impact on
the tumour-initiating capability of injected cells (Quintana et al,
2008). Nevertheless, our data do confirm that different TIC
phenotypes can be identified in the same GBM using fluores-
cence-guided sampling of the M and T.
More importantly, our results identify a non-self-renewing
tumorigenic cell population in human GBM for the first time that
requires further investigation. The identification of a phenotypi-
cally distinct TIC population in the M is potentially extremely
important because this region corresponds to the residual disease
that is subsequently exposed to genotoxic therapy and from which
treatment-resistant recurrent disease emerges. Further investiga-
tion and molecular characterisation of this region will improve our
understanding of the nature of ‘residual disease’ in GBM and
hopefully translate into improvements in the treatment of patients.
ACKNOWLEDGEMENTS
This study was supported by the Evelyn Trust; the National
Institute for Health Research Cambridge Biomedical Research
Centre; the Higher Education Funding Council for England; the
Royal College of Surgeons of Edinburgh; the European Commission-
Seventh Framework Programme (Marie Curie Intra-European
Fellowship to SGMP); and Cancer Research UK and Hutchison
Whampoa Limited.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland
EC, Nam HS, Benezra R (2012) Self-renewal does not predict tumor
growth potential in mouse models of high-grade glioma. Cancer Cell
21(1): 11–24
Fael Al-Mayhani TM, Ball SL, Zhao JW, Fawcett J, Ichimura K, Collins PV,
Watts C (2009) An efficient method for derivation and propagation of
glioblastoma cell lines that conserves the molecular profile of their
original tumours. J Neurosci Methods 176(2): 192–199
Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li
YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL,
Eberhart CG (2010) NOTCH pathway blockade depletes CD133-positive
glioblastoma cells and inhibits growth of tumor neurospheres and
xenografts. Stem Cells 28(1): 5–16
Ferri AL, Cavallaro M, Braida D, Di Cristofano A, Canta A, Vezzani A,
Ottolenghi S, Pandolfi PP, Sala M, DeBiasi S, Nicolis SK (2004) Sox2
deficiency causes neurodegeneration and impaired neurogenesis in the
adult mouse brain. Development 131(15): 3805–3819
Gaiano N, Fishell G (2002) The role of notch in promoting glial and neural
stem cell fates. Annu Rev Neurosci 25: 471–490
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R,
Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of
tumorigenic, stem-like neural precursors from human glioblastoma.
Cancer Res 64(19): 7011–7021
Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P,
Ravetti GL, Zona GL, Daga A, Corte G (2009) SOX2 silencing in
glioblastoma tumor-initiating cells causes stop of proliferation and loss
of tumorigenicity. Stem Cells 27(1): 40–48
Guilfoyle MR, Weerakkody RA, Oswal A, Oberg I, Jeffery C, Haynes K,
Kullar PJ, Greenberg D, Jefferies SJ, Harris F, Price SJ, Thomson S, Watts
C (2011) Implementation of neuro-oncology service reconfiguration in
accordance with NICE guidance provides enhanced clinical care for
patients with glioblastoma multiforme. Br J Cancer 104(12): 1810–1815
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH,
Bronner-Fraser M, Kornblum HI (2003) Cancerous stem cells can arise
from pediatric brain tumors. Proc Natl Acad Sci USA 100(25): 15178–15183
Idoate MA, Diez Valle R, Echeveste J, Tejada S (2011) Pathological
characterization of the glioblastoma border as shown during surgery
using 5-aminolevulinic acid-induced fluorescence. Neuropathology 31(6):
575–582
Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler
DA (2002) Human cortical glial tumors contain neural stem-like cells
expressing astroglial and neuronal markers in vitro. Glia 39(3): 193–206
Lathia JD, Heddleston JM, Venere M, Rich JN (2011) Deadly teamwork:
neural cancer stem cells and the tumor microenvironment. Cell Stem Cell
8(5): 482–485
Lelli SM, San Martin de Viale LC, Mazzetti MB (2005) Response of glucose
metabolism enzymes in an acute porphyria model. Role of reactive
oxygen species. Toxicology 216(1): 49–58
Lelli SM, Mazzetti MB, San Martin de Viale LC (2008) Hepatic alteration of
tryptophan metabolism in an acute porphyria model Its relation with
gluconeogenic blockage. Biochem Pharmacol 75(3): 704–712
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25(4): 402–408
Fluorescence-guided sampling of human glioblastoma
SGM Piccirillo et al
467
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(3), 462 – 468
T
ra
n
sl
a
ti
o
n
a
l
T
h
e
ra
p
e
u
ti
c
s
Opstad KS, Bell BA, Griffiths JR, Howe FA (2008) Toward accurate
quantification of metabolites, lipids, and macromolecules in HRMAS
spectra of human brain tumor biopsies using LCModel.Magn Reson Med
60(5): 1237–1242
Piccirillo SG, Binda E, Fiocco R, Vescovi AL, Shah K (2009a) Brain cancer
stem cells. J Mol Med 87(11): 1087–1095
Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A,
Baronchelli S, Maira G, Pollo B, Mangiola A, DiMeco F, Dalpra L, Vescovi
AL (2009b) Distinct pools of cancer stem-like cells coexist within human
glioblastomas and display different tumorigenicity and independent
genomic evolution. Oncogene 28(15): 1807–1811
Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem
H, Olivi A, Dimeco F, Vescovi AL (2006) Bone morphogenetic proteins
inhibit the tumorigenic potential of human brain tumour-initiating cells.
Nature 444(7120): 761–765
Provencher SW (2001) Automatic quantitation of localized in vivo 1H
spectra with LCModel. NMR Biomed 14(4): 260–264
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ
(2008) Efficient tumour formation by single human melanoma cells.
Nature 456(7222): 593–598
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer,
and cancer stem cells. Nature 414(6859): 105–111
Roberts DW, Valdes PA, Harris BT, Fontaine KM, Hartov A, Fan X, Ji S,
Lollis SS, Pogue BW, Leblond F, Tosteson TD, Wilson BC, Paulsen KD
(2011) Coregistered fluorescence-enhanced tumor resection of malignant
glioma: relationships between delta-aminolevulinic acid-induced proto-
porphyrin IX fluorescence, magnetic resonance imaging enhancement,
and neuropathological parameters. Clinical article. J Neurosurg 114(3):
595–603
Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N,
Kunwar S, Lawton MT, McDermott MW, Parsa AT, Manuel-Garcia
Verdugo J, Berger MS, Alvarez-Buylla A (2004) Unique astrocyte ribbon
in adult human brain contains neural stem cells but lacks chain
migration. Nature 427(6976): 740–744
Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P,
Pumiglia K, Temple S (2004) Endothelial cells stimulate self-renewal and
expand neurogenesis of neural stem cells. Science 304(5675): 1338–1340
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB
(2003) Identification of a cancer stem cell in human brain tumors.
Cancer Res 63(18): 5821–5828
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman
RM, Cusimano MD, Dirks PB (2004) Identification of human brain
tumour initiating cells. Nature 432(7015): 396–401
Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000)
Fluorescence-guided resection of glioblastoma multiforme by using
5-aminolevulinic acid-induced porphyrins: a prospective study in 52
consecutive patients. J Neurosurg 93(6): 1003–1013
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ
(2006) Fluorescence-guided surgery with 5-aminolevulinic acid for
resection of malignant glioma: a randomised controlled multicentre
phase III trial. Lancet Oncol 7(5): 392–401
Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, Goetz AE,
Kiefmann R, Reulen HJ (1998) Intraoperative detection of malignant
gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.
Neurosurgery 42(3): 525–526
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer
RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG,
Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987–996
Tonn JC, Stummer W (2008) Fluorescence-guided resection of malignant
gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls.
Clin Neurosurg 55: 20–26
Valdes PA, Kim A, Brantsch M, Niu C, Moses ZB, Tosteson TD, Wilson BC,
Paulsen KD, Roberts DW, Harris BT (2011) {delta}-aminolevulinic acid-
induced protoporphyrin IX concentration correlates with histopatholo-
gic markers of malignancy in human gliomas: the need for quantitative
fluorescence-guided resection to identify regions of increasing malig-
nancy. Neuro Oncol 13(8): 846–856
Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem cells. Nat Rev
Cancer 6(6): 425–436
Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black
KL, Yu JS (2004) Isolation of cancer stem cells from adult glioblastoma
multiforme. Oncogene 23(58): 9392–9400
This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0
Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/3.0/
Fluorescence-guided sampling of human glioblastoma
SGM Piccirillo et al
468
British Journal of Cancer (2012) 107(3), 462 – 468 & 2012 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
